颅底脑膜瘤中频发的AKT1E17K突变与mTOR及ERK1/2激活相关并缩短肿瘤复发时间
该研究分析了93例颅底脑膜瘤(82例WHO I级,11例WHO II级)的AKT1、KLF4/TRAF7、SMO、PI3K及TERT启动子突变。AKT1E17K突变见于31%的患者,与脑膜上皮型组织学相关,并对肿瘤复发时间有负面影响;AKT1E17K肿瘤中磷酸化mTOR和磷酸化p70S6K阳性率显著更高。结论认为AKT1E17K突变在颅底脑膜瘤中常见,导致mTOR和ERK1/2信号通路激活,对肿瘤复发有负面影响。
要点
- 颅底脑膜瘤中AKT1E17K突变发生率为31%,与脑膜上皮型组织学相关。
- AKT1E17K突变对肿瘤复发时间有负面影响。
- AKT1E17K肿瘤中磷酸化mTOR和磷酸化p70S6K阳性肿瘤比例显著更高。
核心结论
- AKT1E17K突变在颅底脑膜瘤中常见,导致mTOR和ERK1/2信号通路激活,并对肿瘤复发有负面影响。
- 携带AKT1E17K突变的颅底脑膜瘤患者可能从针对mTOR通路的额外治疗中获益。
- PI3K-Akt-mTOR轴可能是这些肿瘤中激酶抑制剂的潜在靶点。
研究设计与样本
- 研究分析了93例颅底脑膜瘤(82例WHO I级,11例WHO II级)中AKT1、KLF4/TRAF7、SMO、PI3K的热点或最相关外显子以及TERT启动子的突变。
主要发现
- AKT1E17K突变存在于31%的患者中,并与脑膜上皮型组织学相关。
- AKT1E17K对肿瘤复发时间有负面影响。
- 在AKT1E17K肿瘤中,磷酸化mTOR和磷酸化p70S6K阳性肿瘤的比例显著更高。
- AKT1E17K肿瘤中磷酸化ERK1/2免疫表达者相比AKT1野生型肿瘤表达磷酸化ERK1/2者,肿瘤复发时间显著更短(P = .046)。
- KLF4突变(K409Q)存在于11.8%的病例中,与分泌型/过渡型亚型显著相关(P < .001);KLF4 K409Q突变的存在与良好结局相关。
临床怎么用
- 作者认为携带AKT1E17K突变的颅底脑膜瘤患者可能从针对mTOR通路的额外治疗中获益。
- 作者认为PI3K-Akt-mTOR轴可能是这些肿瘤中激酶抑制剂的潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Skull base meningiomas are considered to be difficult for surgical treatment. We wondered whether genetic alterations recently identified in benign non-NF2-mutated World Health Organization (WHO) grade I meningiomas are related to clinical features of skull base meningiomas and whether druggable signaling pathways are activated. METHODS: We analyzed 93 skull base meningiomas (82 WHO grade I, 11 WHO grade II) for mutations of hot spots or the most relevant exons of AKT1, KLF4/TRAF7, SMO, PI3K, and the TERT promoter. RESULTS: The AKT1E17K mutation was present in 31% of patients and was related to meningothelial histology. AKT1E17K had a negative effect on the time to tumor recurrence. Analyses of activated signaling proteins revealed among AKT1E17K tumors a significantly higher rate of phospho-mammalian target of rapamycin (mTOR) and phospho-p70S6K+ tumors. AKT1E17K tumors with immunoexpression of phospho-extracellular signal-regulated kinase 1 or 2 (ERK1/2) were characterized by significantly shorter time to tumor recurrence compared with AKT1wt tumors expressing phospho-ERK1/2 (P = .046). KLF4 mutations (K409Q) were present in 11.8% of cases, with significant association to the secretory/transitional subtype (P < .001). The presence of the KLF4 K409Q mutation was associated with favorable outcome. One phosphatidylinositol-3 kinase (PI3K) mutation but no SMO or TERT promoter mutation was found. CONCLUSIONS: AKT1E17K mutation is frequent in skull base meningiomas, results in activation of the mTOR and ERK1/2 signaling pathways, and has negative impact on tumor recurrence. Patients with skull base meningiomas with AKT1E17K mutation might benefit from additional treatment targeting the mTOR pathway. Generally, the PI3K-Akt-mTOR axis might be a potential target for kinase inhibitors in these tumors.
引用
- Yesilöz Ü, Kirches E, Hartmann C, et al. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro Oncol. 2017. PMID: 28482067. doi:10.1093/neuonc/nox018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。